ArticleAlimentary pharmacology & therapeutics2014

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.

P Schoenfeld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.